1-苯并噻吩-5-腈 | 2060-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-苯并噻吩-5-腈
• 中文别名: 苯并噻吩-5-腈；苯并[B]噻吩-5-氰基
• 英文名称: benzo[b]thiophene-5-carbonitrile
• 英文别名: 1-benzothiophene-5-carbonitrile；5-cyanobenzothiophene
• CAS: 2060-63-1
• 化学式: C₉H₅NS
• mdl: MFCD05664404
• 分子量: 159.211
• InChiKey: IPJUOWGTGHKFKN-UHFFFAOYSA-N

物化性质

• 熔点：
  69 °C
• 沸点：
  130-140 °C(Press: 7 Torr)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 海关编码：
  2934999090
• 安全说明：
  S22,S26,S36/37/39
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Name:	1-Benzothiophene-5-carbonitrile Material Safety Data Sheet
Synonym:	None Known
CAS:	2060-63-1

Section 1 - Chemical Product MSDS Name:1-Benzothiophene-5-carbonitrile Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2060-63-1	1-Benzothiophene-5-carbonitrile	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin. May be metabolized to cyanide which in turn acts by inhibiting cytochrome oxidase impairing cellular respiration.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Metabolism may release cyanide, which may result in headache, dizziness, weakness, collapse, unconsciousness and possible death.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation. May be metabolized to cyanide which in turns act by inhibiting cytochrome oxidase impairing cellular respiration.
Chronic:
Exposure to small amounts of cyanide compounds over long periods of time is reported to cause loss of appetite, headache, weakness, nausea, dizziness, and symptoms of irritation of the upper respiratory tract and eyes.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2060-63-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Grey
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 68.5 - 71 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H5NS
Molecular Weight: 159.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2060-63-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Benzothiophene-5-carbonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, LIQUID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 76
Packing Group: III
IMO
Shipping Name: NITRILES, LIQUID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 76
Packing Group: III
RID/ADR
Shipping Name: NITRILES, LIQUID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 76
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 2060-63-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2060-63-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2060-63-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苯并噻吩-5-腈 在 盐酸 、 水 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 60.0h， 生成 1-苯并噻吩-5-羧酸甲酯
  参考文献：
  名称：

  NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS

  摘要：

  本发明涉及一种新型的二氢吡啶衍生物，其化学式为(I)：作为选择的核受体调节剂，所述核受体包括雄激素受体和糖皮质激素受体，以及其制备方法，包括所述化合物的制药组合物和利用所述化合物制造用于治疗可以通过调节雄激素受体和/或糖皮质激素受体改善的病理情况或疾病的药物，所述病理情况或疾病包括癌症、转移性癌症、良性前列腺增生、多囊卵巢综合征（PCOS）、脱发、多毛症、痤疮、性腺功能减退、肌肉消耗性疾病、虚弱、库欣综合征、抗精神病药物诱导的体重增加、肥胖、创伤后应激障碍和酗酒。

  公开号：

  EP3480201A1
• 作为产物：
  描述：

  5-溴-2-氟苯甲醛 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 potassium hydroxide 作用下， 以 N-甲基吡咯烷酮 、 乙醇 、 N,N-二甲基乙酰胺 、 水 、 二甲基亚砜 为溶剂， 反应 19.0h， 生成 1-苯并噻吩-5-腈
  参考文献：
  名称：

  Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

  摘要：

  The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 mu M and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 mu M). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 +/- 0.37 mu M). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b01374

文献信息

• Ni-Catalyzed Reductive Cyanation of Aryl Halides and Phenol Derivatives via Transnitrilation
  作者：L. Reginald Mills、Joshua M. Graham、Purvish Patel、Sophie A. L. Rousseaux

  DOI：10.1021/jacs.9b11208

  日期：2019.12.11

  reductive coupling for the synthesis of benzonitriles from aryl (pseudo)halides and an electrophilic cyanating reagent, 2-methyl-2-phenyl malononitrile (MPMN). MPMN is a bench-stable, carbon-bound electrophilic CN reagent that does not release cyanide under the reaction conditions. A variety of medicinally relevant benzonitriles can be made in good yields. Addition of NaBr to the reaction mixture allows for

  在此，我们报告了一种 Ni 催化的还原偶联，用于从芳基（伪）卤化物和亲电氰化试剂 2-甲基-2-苯基丙二腈 (MPMN) 合成苯甲腈。MPMN 是一种工作台稳定的碳键合亲电子 CN 试剂，在反应条件下不会释放氰化物。可以以良好的收率制备多种与药用相关的苯甲腈。将 NaBr 添加到反应混合物中可以使用更具挑战性的芳基亲电试剂，例如芳基氯化物、甲苯磺酸盐和三氟甲磺酸盐。机理研究表明，溴化钠在促进这些底物的氧化加成方面发挥作用。
• Palladium-Catalyzed Synthesis of Aryl Nitriles: Using α-Imino­nitrile as Cyano Source for Aryl Halide Cyanations
  作者：Yong-Ming Zhu、Yu-Long Shi、Qing Yuan、Zhen-Bang Chen、Fang-Ling Zhang、Kui Liu

  DOI：10.1055/s-0036-1591501

  日期：2018.2

  An efficient and ligand-free palladium-catalyzed exchange reaction to synthesize aryl nitriles by using α-iminonitrile as a starting reagent has been developed. This methodology provides an optional method for the synthesis of aryl nitriles with moderate to good yields. At the same time, this approach is adaptable for many substrates.

  开发了一种高效且无配体的钯催化交换反应，以 α-亚氨基腈为起始试剂合成芳基腈。这种方法为合成芳基腈提供了一种可选的方法，收率中等至良好。同时，这种方法适用于许多基材。
• “One-pot” synthesis of amidoxime via Pd-catalyzed cyanation and amidoximation
  作者：Chu-Ting Yang、Jun Han、Jun Liu、Mei Gu、Yi Li、Jun Wen、Hai-Zhu Yu、Sheng Hu、Xiaolin Wang

  DOI：10.1039/c4ob02456g

  日期：——

  “One-pot” synthesis of amidoxime was developed for studies on the interactions between amidoxime and uranyl.

  “一锅法”合成酰胺肟，用于研究酰胺肟与铀酰之间的相互作用。
• Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide⋅⋅⋅Heteroarene π-Stacking Interactions and Chalcogen Bonding in the S3 Pocket
  作者：Maude Giroud、Jakov Ivkovic、Mara Martignoni、Marianne Fleuti、Nils Trapp、Wolfgang Haap、Andreas Kuglstatter、Jörg Benz、Bernd Kuhn、Tanja Schirmeister、François Diederich

  DOI：10.1002/cmdc.201600563

  日期：2017.2.3

  We report an extensive “heteroarene scan” of triazine nitrile ligands of the cysteine protease human cathepsin L (hCatL) to investigate π‐stacking on the peptide amide bond Gly67–Gly68 at the entrance of the S3 pocket. This heteroarene⋅⋅⋅peptide bond stacking was supported by a co‐crystal structure of an imidazopyridine ligand with hCatL. Inhibitory constants (Ki) are strongly influenced by the diverse

  我们报道了半胱氨酸蛋白酶人组织蛋白酶L（hCatL）的三嗪腈配体的广泛的“杂芳烃扫描”，以研究S3口袋入口处的肽酰胺键Gly67–Gly68上的π堆积。杂芳基·····肽键的堆叠由咪唑并吡啶配体与hCatL的共晶体结构支持。抑制常数（ķ我）受到杂环的多样性和与S3口袋局部环境的特定相互作用的强烈影响。结合亲和力变化三个数量级。与烃类似物相比，所有杂芳族配体均具有增强的结合力。从杂芳烃和肽键的局部偶极矩的方向预测的能量贡献无法得到证实。分子间的C-S⋅⋅⋅O= C相互作用（硫族元素键）与Asn66的主链C = O增强了苯并噻吩基（K i = 4 n m）和苯并噻唑基（K i = 17 n m）配体的结合。 S3口袋。还测试了配体的相关酶罗德沙星。
• [EN] SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS SPIRO-OXADIAZOLINE EN TANT QU'AGONISTES DES RÉCEPTEURS DE L'ACÉTYLCHOLINE Α-7 NICOTINIQUE
  申请人：FORUM PHARMACEUTICALS INC

  公开号：WO2015066371A1

  公开（公告）日：2015-05-07

  The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及新型螺环-噁二唑啉化合物，适用作a7-nAChR的激动剂或部分激动剂，以及这些化合物和组合物的制备方法、药物组合物，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物。具体而言，涉及向需要的患者（例如患有认知缺陷和/或希望增强认知功能的患者）施用螺环-噁二唑啉cx7-nAChR激动剂或部分激动剂的方法，以使其获益。

表征谱图